Bayer and Zydus Cadila sign JV Agreement Bayer Health care and the Indian business Zydus Cadila signed an contract in Mumbai, India, to create the Joint Venture Firm Bayer Zydus Pharma. With this newly established advertising and sales enterprise, Bayer aims to improve its existence in the fast developing pharmaceutical marketplace in India frustrating issue . Each ongoing party will hold 50 % of the shares of Bayer Zydus Pharma, and become represented on its administration board equally. For Bayer Health care the forming of Bayer Zydus Pharma is normally an essential element of the business’s strategy to create a stronger existence in the emerging marketplaces.
Bayer: Very successful begin to 2014 Product sales of the Bayer Group advanced by 2.8 % in the first quarter of 2014 to EUR 10,555 million . Adjusted for currency and portfolio results , business extended by 8.4 %. EBIT rose by 18.4 % to EUR 2,096 million after net special components of plus EUR 7 million . EBIT before special products elevated by 15.0 % to EUR 2,089 million . Regardless of negative currency ramifications of some EUR 200 million or roughly 8 %, EBITDA before unique items improved by 11.6 % to EUR 2,738 million .